Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo
Tao Liu,1,* Tingting Jia,2,* Xia Yuan,2 Cheng Liu,1 Jian Sun,1 Zhenhua Ni,1 Jian Xu,1 Xuhui Wang,2 Yi Yuan2 1Centralab, 2Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China *These authors contributed equally to...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Dove Medical Press
2016-05-01
|
| Series: | International Journal of Nanomedicine |
| Subjects: | |
| Online Access: | https://www.dovepress.com/development-of-octreotide-conjugated-polymeric-prodrug-of-bufalin-for--peer-reviewed-article-IJN |
| _version_ | 1818683588437082112 |
|---|---|
| author | Liu T Jia T Yuan X Liu C Sun J Ni Z Xu J Wang X Yuan Y |
| author_facet | Liu T Jia T Yuan X Liu C Sun J Ni Z Xu J Wang X Yuan Y |
| author_sort | Liu T |
| collection | DOAJ |
| description | Tao Liu,1,* Tingting Jia,2,* Xia Yuan,2 Cheng Liu,1 Jian Sun,1 Zhenhua Ni,1 Jian Xu,1 Xuhui Wang,2 Yi Yuan2 1Centralab, 2Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Development of polymeric prodrugs of small molecular anticancer drugs has become one of the most promising strategies to overcome the intrinsic shortcomings of small molecular anticancer drugs and improve their anticancer performance. Materials and methods: In the current work, we fabricated a novel octreotide (Oct)-modified esterase-sensitive tumor-targeting polymeric prodrug of bufalin (BUF) and explored its anticancer performance against somatostatin receptor 2 overexpressing breast cancer. Results: The obtained tumor-targeting polymeric prodrug of BUF, P(oligo[ethylene glycol] monomethyl ether methacrylate [OEGMA]-co-BUF-co-Oct), showed a nanosize dimension and controlled drug release features in the presence of esterase. It was demonstrated by in vitro experiment that P(OEGMA-co-BUF-co-Oct) showed enhanced cytotoxicity, cellular uptake, and apoptosis in comparison with those of free BUF. In vivo experiment further revealed the improved accumulation of drugs in tumor tissues and enhanced anticancer performance of P(OEGMA-co-BUF-co-Oct). Conclusion: Taken together, this study indicated that polymeric prodrug of BUF holds promising potential toward the treatment of somatostatin receptor 2 overexpressing breast cancer. Keywords: esterase responsive, controlled release, tumor targeting |
| first_indexed | 2024-12-17T10:37:07Z |
| format | Article |
| id | doaj.art-c8e9503fbe344efeb5e1a26c5d1eebc1 |
| institution | Directory Open Access Journal |
| issn | 1178-2013 |
| language | English |
| last_indexed | 2024-12-17T10:37:07Z |
| publishDate | 2016-05-01 |
| publisher | Dove Medical Press |
| record_format | Article |
| series | International Journal of Nanomedicine |
| spelling | doaj.art-c8e9503fbe344efeb5e1a26c5d1eebc12022-12-21T21:52:21ZengDove Medical PressInternational Journal of Nanomedicine1178-20132016-05-012016default2235225027064Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivoLiu TJia TYuan XLiu CSun JNi ZXu JWang XYuan YTao Liu,1,* Tingting Jia,2,* Xia Yuan,2 Cheng Liu,1 Jian Sun,1 Zhenhua Ni,1 Jian Xu,1 Xuhui Wang,2 Yi Yuan2 1Centralab, 2Department of Pharmacy, Putuo Hospital, Shanghai University of Traditional Chinese Medicine, Shanghai, People’s Republic of China *These authors contributed equally to this work Background: Development of polymeric prodrugs of small molecular anticancer drugs has become one of the most promising strategies to overcome the intrinsic shortcomings of small molecular anticancer drugs and improve their anticancer performance. Materials and methods: In the current work, we fabricated a novel octreotide (Oct)-modified esterase-sensitive tumor-targeting polymeric prodrug of bufalin (BUF) and explored its anticancer performance against somatostatin receptor 2 overexpressing breast cancer. Results: The obtained tumor-targeting polymeric prodrug of BUF, P(oligo[ethylene glycol] monomethyl ether methacrylate [OEGMA]-co-BUF-co-Oct), showed a nanosize dimension and controlled drug release features in the presence of esterase. It was demonstrated by in vitro experiment that P(OEGMA-co-BUF-co-Oct) showed enhanced cytotoxicity, cellular uptake, and apoptosis in comparison with those of free BUF. In vivo experiment further revealed the improved accumulation of drugs in tumor tissues and enhanced anticancer performance of P(OEGMA-co-BUF-co-Oct). Conclusion: Taken together, this study indicated that polymeric prodrug of BUF holds promising potential toward the treatment of somatostatin receptor 2 overexpressing breast cancer. Keywords: esterase responsive, controlled release, tumor targetinghttps://www.dovepress.com/development-of-octreotide-conjugated-polymeric-prodrug-of-bufalin-for--peer-reviewed-article-IJNPolymeric ProdrugBreast CancerControlled ReleaseBufalin |
| spellingShingle | Liu T Jia T Yuan X Liu C Sun J Ni Z Xu J Wang X Yuan Y Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo International Journal of Nanomedicine Polymeric Prodrug Breast Cancer Controlled Release Bufalin |
| title | Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo |
| title_full | Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo |
| title_fullStr | Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo |
| title_full_unstemmed | Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo |
| title_short | Development of octreotide-conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo |
| title_sort | development of octreotide conjugated polymeric prodrug of bufalin for targeted delivery to somatostatin receptor 2 overexpressing breast cancer in vitro and in vivo |
| topic | Polymeric Prodrug Breast Cancer Controlled Release Bufalin |
| url | https://www.dovepress.com/development-of-octreotide-conjugated-polymeric-prodrug-of-bufalin-for--peer-reviewed-article-IJN |
| work_keys_str_mv | AT liut developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT jiat developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT yuanx developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT liuc developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT sunj developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT niz developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT xuj developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT wangx developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo AT yuany developmentofoctreotideconjugatedpolymericprodrugofbufalinfortargeteddeliverytosomatostatinreceptor2overexpressingbreastcancerinvitroandinvivo |